Genzyme To Expand Presence In Oncology Through Licensing Deals In 2004
Executive Summary
Genzyme is looking to expand its presence in oncology through in-licensing activities in 2004
You may also be interested in...
FTC Allows Genzyme/Novazyme Merger, Finds No Product Development Delay
The merger of Genzyme and Novazyme does not merit antitrust activity because it does not result in the delay of Pompe therapy development, the Federal Trade Commission said Jan. 13
Schering Hunting Biotech Deals To Complement Specialty Portfolio
Schering-Plough is focusing its in-licensing activities on specialty biotechnology products, CEO Fred Hassan told analysts during the company's business review in New York City Nov. 18
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011